Hepatitis C virus (HCV) infection is a significant global public health problem. In developed countries, 90% of new infections occur among people who inject drugs (PWID), with seroprevalence increasing rapidly among new injectors. Staying Safe is an international, qualitative, social research project, the aim of which is to draw on the experiences of long-term PWID to inform a new generation of HCV prevention strategies. The Sydney project team employed life history interviews and computer-generated timelines to elicit detailed data about unexposed participants’ (n =13) injecting practices, circumstances, and social networks over time. The motivations and strategies that enabled participants to avoid risk situations, and which might have helped them to “stay safe,” appeared not to be directly related to harm-reduction messages or HCV avoidance. These included the ability and inclination to maintain social and structural resources, to mainly inject alone, to manage withdrawal, and to avoid injecting-related scars. These findings point to the multiple priorities that facilitate viral avoidance among PWID and the potential efficacy of nonspecific HCV harm-reduction interventions for HCV prevention.
Australian Injecting and Illicit Drug Users League. (2010). Legislative and policy barriers to needle & syringe programs and injecting equipment access for people who inject drugs. Canberra, Australia: Author. Retrieved from http://www.aivl.org.au/files/29057-AIVL-book-text_FA.pdf
2.
BlackwellJ. S. (1983). Drifting, controlling and overcoming: Opiate users who avoid becoming chronically dependent. Journal of Drug Issues, 13, 219-235.
3.
BoeriM. W. (2004). “Hell, I'm an addict, but I ain’t no junkie”: An ethnographic analysis of aging heroin users. Human Organization, 63, 236-245. Retrieved from http://works.bepress.com/miriam_boeri/9/
4.
BourgoisP.PrinceB.MossA. (2004). The everyday violence of hepatitis C among young women who inject drugs in San Francisco. Human Organization, 63, 253-264.
5.
CohenP.SasA. (1994). Cocaine use in Amsterdam in non-deviant subcultures. Addiction Research, 2, 71-94. doi:10.3109/1606635940900554710.3109/16066359409005547
6.
FraserS. (2004). “It’s your life!”: Injecting drug users, individual responsibility and hepatitis C prevention. Health, 8, 199-221. doi:10.1177/136345930404107010.1177/1363459304041070
7.
FraserS.TreloarC. (2006). ‘Spoiled identity’ in hepatitis C infection: The binary logic of despair. Critical Public Health, 16, 99-110. doi:10.1080/0958159060082868310.1080/09581590600828683
8.
FriedmanS.Mateu-GelabertP.SandovalM.HaganH.Des JarlaisD. (2008). Positive deviance control-case life history: A method to develop grounded hypotheses about successful long-term avoidance of infection. BMC Public Health 8, 1-10. doi:10.1186/1471-2458-8-9410.1186/1471-2458-8-94
9.
GlaserB.StraussA. (1967). Discovery of grounded theory: Strategies for qualitative research. Chicago: Aldine de Gruyter.
10.
GoffmanE. (1963). Stigma: Notes on the management of a spoiled identity. Middlesex, UK: Penguin.
11.
GrundJ. P.FriedmanS.SternL.JoseB.NeaigusA.CurtisR.Des JarlaisD. (1996). Syringe-mediated sharing among injecting drug users: Patterns, social context and implications for transmission of blood-borne pathogens. Social Science and Medicine, 42, 691-703. doi:10.1016/0277-9536(95)00193-X10.1016/0277-9536(95)00193-X
12.
HaganH.CampbellJ.ThiedeH.StrathdeeS.OuelletL.LatkaM.GarfeinR. (2007). Injecting alone among young adult IDUs in five US cities: Evidence of low rates of injection risk behavior. Drug and Alcohol Dependence, 91, S48-S55. doi:10.1016/j.drugalcdep.2007.02.00210.1016/j.drugalcdep.2007.02.002
13.
HaganH.PougetE. R.WilliamsI. T.GarfeinR. L.StrathdeeS. A.HudsonS. M.OuelleyL. J. (2010). Attribution of hepatitis C virus seroconversion risk in young injection drug users in 5 US cities. Journal of Infectious Diseases, 201, 378-385. doi:10.1086/64978310.1086/649783
14.
HarrisM. (2005). Living with hepatitis C: The medical encounter. New Zealand Sociology, 20, 4-19.
15.
HarrisM. (2009). Injecting, infection, illness: Abjection and hepatitis C stigma. Body & Society, 15(4), 33-51. doi:10.1177/1357034X0934722110.1177/1357034X09347221
16.
HarrisM. (2010). Pleasure and guilt: Alcohol use and hepatitis C. Qualitative Health Research, 20, 1262-1271. doi:10.1177/ 104973231036764110.1177/ 1049732310367641
HeckathornD. (1997). Respondent-driven sampling: A new approach to the study of hidden populations. Social Problems, 44, 174-199. doi:10.1525/sp.1997.44.2.03x0221m10.1525/sp.1997.44.2.03x0221m
19.
HeimerR.ClairS.GrauL. E.BluthenthalR. N.MarshallP. A.SingerM. (2002). Hepatitis-associated knowledge is low and risks are high among HIV-aware injection drug users in three US cities. Addiction, 97, 1277-1287. doi:10.1046/j.1360-0443.2002.t01-1-00211.x10.1046/j.1360-0443.2002.t01-1-00211.x
20.
HubbardG. (2000). The usefulness of in-depth life history interviews for exploring the role of social structure and human agency in youth transitions. Sociological Research Online, 4. Retrieved from http://ideas.repec.org/a/sro/srosro/1999-84-3.html
21.
HuntD. E. (1997). A selected bibliography on the drug use(r) “career.”Substance Use & Misuse, 32, 283-291. doi:10.3109/1082608970905585110.3109/10826089709055851
22.
JacksonL.ParkerJ.DykemanM.GahaganJ.KarabanowJ.(2010). The power of relationships: Implications for safer and unsafe practices among injection drug users. Drugs: Education, Prevention and Policy, 17, 189-204. doi:10.1080/0968763080237887210.1080/09687630802378872
23.
KimD.IrwinK.KhoshnoodK. (2009). Expanded access to naloxone: Options for critical response to the epidemic of opioid overdose mortality. American Journal of Public Health, 99, 402-407. doi:10.2105/AJPH.2008.13693710.2105/AJPH.2008.136937
24.
LappingK.MarshD. R.RosenbaumJ.SwedbergE.SterninJ.SterninM.SchoederD. G. (2002). The positive deviance approach: Challenges and opportunities for the future. Food and Nutrition Bulletin, 23, 130-137. Retrieved from www.ncbi.nlm.nih.gov/pubmed/12503241
25.
LavanchyD. (2008). Chronic viral hepatitis as a public health issue in the world. Best Practice & Research Clinical Gastroenterology, 22, 991-1008. doi:10.1016/j.bpg.2008.11.00210.1016/j.bpg.2008.11.002
MaherL. (2002). Don’t leave us this way: Ethnography and injecting drug use in the age of AIDS. International Journal of Drug Policy, 13, 311-325. doi:10.1016/S0955-3959(02)00118-410.1016/S0955-3959(02)00118-4
28.
MaherL.LiJ.JalaludinB.ChantK.KaldorJ. (2007). High hepatitis C incidence in new injecting drug users: A policy failure?Australian New Zealand Journal of Public Health, 31, 30-35. doi:10.1111/j.1753-6405.2007.0000710.1111/j.1753-6405.2007.00007
29.
MaherL.WhiteB.HellardM.MaddenA.PrinsM.KerrT.PageK. (2010). Candidate hepatitis C vaccine trials and people who inject drugs: Challenges and opportunities. Vaccine, 28, 7273-7278. doi:10.1016/ j.vaccine.2010.08.08510.1016/ j.vaccine.2010.08.085
30.
Mateu-GelabertP.SandovalM.MeylakhsP.WendelT.FriedmanS. R. (2010). Strategies to avoid opiate withdrawal: Implications for HCV and HIV risks. International Journal of Drug Policy, 21, 179-185. doi:10.1016/j.drugpo.2009.08.00710.1016/j.drugpo.2009.08.007
31.
Mateu-GelabertP.TreloarC.CalatayudV. A.SandovalM.ZuriánJ. C.MaherL.FriedmanS. R. (2007). How can hepatitis C be prevented in the long term?International Journal of Drug Policy, 18, 338-340. doi:10.1016/j.drugpo.2007.06.00110.1016/j.drugpo.2007.06.001
32.
MillerP. G. (2009). Safe using messages may not be enough to promote behavior change amongst injecting drug users who are ambivalent or indifferent towards death. Harm Reduction Journal, 6(18), 1-8. doi:10.1186/1477-7517-6-1810.1186/1477-7517-6-18
33.
MooreD. (2004). Governing street-based injecting drug users: A critique of heroin overdose prevention in Australia. Social Science & Medicine, 59, 1547-1557. doi:10.1016/j.socscimed.2004.01.02910.1016/j.socscimed.2004.01.029
PageK.HahnJ. A.EvansJ.ShiboskiS.LumP.DelwartE.BuschM. P. (2009). Acute hepatitis C virus infection in young adult injection drug users: A prospective study of incident infection, resolution, and reinfection. Journal of Infectious Diseases, 200, 1216-1226. doi:10.1086/60594710.1086/605947
37.
PalmateerN.KimberJ.HickmanM.HutchinsonS.RhodesT.GoldbergD. (2010). Evidence for the effectiveness of sterile injecting equipment provision in preventing hepatitis C and human immunodeficiency virus transmission among injecting drug users: A review of reviews. Addiction, 105, 844-859. doi:10.1111/j.1360-0443.2009.02888.x10.1111/j.1360-0443.2009.02888.x
38.
RadcliffeP.StevensA. (2008). Are drug treatment services only for ‘thieving junkie scumbags’? Drug users and the management of stigmatized identities. Social Science and Medicine, 67, 1065-1073. doi:10.1016/j.socscimed.2008.06.00410.1016/j.socscimed.2008.06.004
39.
RhodesT. (2002). The ‘risk environment’: A framework for understanding and reducing drug-related harm. International Journal of Drug Policy, 13, 85-94. doi:10.1016/S0955-3959(02)00007-510.1016/S0955-3959(02)00007-5
40.
RhodesT.DavisM.JuddA. (2004). Hepatitis C and its risk management among drug injectors in London: Renewing harm reduction in the context of uncertainty. Addiction, 99, 621-633. doi:10.1111/j.1360-0443.2004.00692.x10.1111/j.1360-0443.2004.00692.x
41.
RhodesT.KimberJ.SmallW.FitzgeraldJ.KerrT.HickmanM.HollowayG. (2006). Public injecting and the need for ‘safer environment interventions’ in the reduction of drug-related harm. Addiction, 101, 1384-1393. doi:10.1111/j.1360-0443.2006.01556.x10.1111/j.1360-0443.2006.01556.x
42.
RhodesT.WattsL.DaviesS.MartinA.SmithJ.ClarkD.LyonsM. (2007). Risk, shame and the public injector: A qualitative study of drug injecting in South Wales. Social Science & Medicine, 65, 572-585. doi:10.1016/j.socscimed.2007.03.03310.1016/j.socscimed.2007.03.033
43.
StuckeyH. L.BoanJ.KraschnewskiJ. L.Miller-DayM.LehmanE. B.SciamannaC. N. (2010). Using positive deviance for determining successful weight-control practices. Qualitative Health Research, 20, 563-579. doi:10.1177/104973231038662310.1177/1049732310386623
44.
ThomasD. L.AstemborskiJ.RaiR. M.AnaniaF. A.SchaefferM.GalaiN.VlahovD. (2000). The natural history of hepatitis C virus infection: Host, viral, and environmental factors. JAMA, 284, 450-456. doi:10.1001/jama.284.4.45010.1001/jama.284.4.450
45.
Timeline Maker Professional. (2009). (Version 2.1.6.2) [Computer software]. Nova Scotia, Canada: Progeny Software. Retrieved from www.timelinemaker.com
46.
TreloarC.AbelsonJ. (2005). Information exchange among injecting drug users: A role for an expanded peer education workforce. International Journal of Drug Policy, 16, 46-53. doi:10.1016/j.drugpo.2004.07.00410.1016/j.drugpo.2004.07.004
47.
TreloarC.FraserS. (2004). Hepatitis C, blood and models of the body: New directions for public health. Critical Public Health, 14, 377-389. doi:10.1080/0958159040002749410.1080/09581590400027494
48.
TreloarC.LaybuttB.JaunceyM.van BeekI.LodgeM.MalpasG.CarruthersS. (2008). Broadening discussions of “safe” in hepatitis C prevention: A close-up of swabbing in an analysis of video recordings of injecting practice. International Journal of Drug Policy, 19, 59-65. doi:10.1016/j.drugpo.2007.01.00510.1016/j.drugpo.2007.01.005
49.
TreloarC.RhodesT. (2009). The lived experience of hepatitis C and its treatment among injecting drug users: Qualitative synthesis. Qualitative Health Research, 19, 1321-1334. doi:10.1177/104973230934165610.1177/1049732309341656
50.
VickermanP.HickmanM.JuddA. (2007). Modelling the impact on hepatitis C transmission of reducing syringe sharing: London case study. International Journal of Epidemiology, 36, 396-405. doi:10.1093/ije/dyl27610.1093/ije/dyl276
51.
WalkerL.SterlingB.HokeM.DeardenK. (2007). Applying the concept of positive deviance to public health data: A tool for reducing health disparities. Public Health Nursing, 24, 571-576. doi:10.1111/j.1525-1446.2007.00670.x10.1111/j.1525-1446.2007.00670.x
52.
ZinbergN. E. (1984). Drug, set and setting. New Haven, CT: Yale University Press.
